Europe
WHO: New measures needed to reduce high drug costs
March 26, 2015Research and Development, Sales and Marketing Europe, WHO, pricing, transparency, world health organization
New approaches to drug pricing and reimbursement are needed to make sure pharma provides access to new medicines, according to …
Chiesi’s stem cell therapy approved in Europe
February 23, 2015Research and Development, Sales and Marketing Chiesi, EC, Europe, Holoclar, Holostem Advanced Therapies, LSCD, stem cell
Chiesi’s Holoclar has become the first stem cell therapy to get the green light in Europe, gaining conditional approval from …
EMA launches consultation on clinical trials
January 22, 2015Research and Development, Sales and Marketing EFPIA, EMA, EU, Europe, Goldacre, alltrials, transparency
The European Medicines Agency has invited pharma to comment on its proposals to ramp up transparency in the industry and …
Lilly to market stomach cancer drug in Europe
December 22, 2014Sales and Marketing Eli Lilly, Europe, FDA, US, cyramza, ramucirumab, stomach cancer
Eli Lilly has been granted permission by the European Commission to market Cyramza in Europe. Lilly’s Cyramza (ramucirumab) is the …
GSK Ebola vaccine gets EU support
December 17, 2014Research and Development, Sales and Marketing EC, EU, Ebola, Europe, GSK, Merck, Takeda, Vaccine, WHO, johnson
A newly-formed European consortium is to help advance the development of GlaxoSmithKline’s promising Ebola vaccine. The consortium is backed by …
Boehringer’s lung cancer drug Vargatef sees EU approval
November 28, 2014Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef
Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …
Europe must prepare for COPD ‘timebomb’
November 19, 2014Sales and Marketing COPD, Europe, European COPD Coalition, Spiriva, asthma, chronic obstructive pulmonary disease
Health services in Europe are not making sufficient effort to cope with the escalating burden of chronic obstructive pulmonary disease …
EMA in turmoil as top job ‘annulled’
November 17, 2014Sales and Marketing EC, EMA, EU, Europe, Guido Rasi, Rasi, transparency
The future of Guido Rasi, head of Europe’s drugs regulator, is up in the air after a legal ruling which …
Telemedicine EU market ‘expected to triple’ by 2020
July 8, 2014Medical Communications, Sales and Marketing Europe, Frost & Sullivan, analysts, telemedicine
The telemedicine market in Europe is poised for rapid growth and can help keep overall healthcare costs down, according to …
Janssen abandons Simponi application
May 23, 2014Sales and Marketing Europe, Janssen, RA, Simponi, rheumatoid arthritis
Janssen Biologics has withdrawn its application to add an intravenous (IV) form to the marketing authorisation of veteran rheumatoid arthritis …
EMA to conduct major review into testosterone drugs
April 14, 2014Research and Development, Sales and Marketing EMA, EU, Europe, heart, testosterone
The European Medicines Agency has started a review of testosterone-containing medicines as concerns grow that they may increase the risk …
EMA transparency agenda sees more delay
April 9, 2014Medical Communications, Sales and Marketing AbbVie, EFPIA, EMA, Europe, InterMune, alltrials, parliament, transparency
The European Medicines Agency is to further delay its policy over clinical trial transparency, saying it needs more time to …
Votrient’s extended licence application ditched
April 1, 2014Sales and Marketing EMA, Europe, GSK, ovarian, votrient kidney cancer
GlaxoSmithKline admits it is ‘disappointed’ after abandoning its attempt to extend kidney cancer drug Votrient’s licence to take in ovarian …
Europe to vote on greater trial transparency
December 17, 2013Research and Development, Sales and Marketing EU, Europe, Goldacre, alltrials, transparency
Pharma companies and academic researchers will be obliged to upload the results of all their European clinical trials to a …
Billions spent on European cancer care
October 15, 2013Research and Development, Sales and Marketing Cancer, Europe, Lancet, Oxford, Pfizer
A new report has shown that cancer cost the European Union a total of €126 billion in 2009, with healthcare …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
